Autologous tumor antigens presented by alpha-type-1 dendritic cells (alpha-DC1-presented antigens)

Autologous tumor antigens presented by alpha-type-1 dendritic cells (alpha-DC1) represent a personalized immunotherapy strategy designed to elicit a robust anti-tumor immune response (Kalinski et al., 2013). In this approach, a patient's own dendritic cells are harvested and matured using a specific cytokine cocktail (typically including IL-1beta, TNF-alpha, IFN-alpha, IFN-gamma, and poly-I:C) to polarize them into the alpha-DC1 phenotype (Lee et al., 2015). These cells are then pulsed with autologous tumor antigens, often derived from whole tumor lysate, allowing them to present a broad spectrum of patient-specific neoantigens and tumor-associated antigens via MHC class I and II molecules. The alpha-DC1 cells are characterized by their high production of interleukin-12 (IL-12p70), which is critical for the induction of potent type-1 immune responses, including the activation of cytotoxic T lymphocytes (CTLs) and Th1 cells. This therapeutic modality is primarily investigated in oncology, particularly for high-grade gliomas and other solid tumors, where it aims to overcome the immunosuppressive tumor microenvironment (NCI Thesaurus). By utilizing the full repertoire of a patient's tumor antigens, the strategy seeks to minimize the risk of immune escape while maximizing the specificity of the immune attack.

Other names

Alpha-type-1 polarized dendritic cell-presented antigensalpha-DC1-loaded autologous tumor antigensAutologous tumor lysate-pulsed alpha-DC1alpha-DC1 vaccine

Dendritic cell-mediated activation of tumor-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells through the presentation of tumor-derived peptides on MHC molecules in the presence of high IL-12 levels.